Cancer Ablation by Water Vapor
Francis Medical is developing novel, disruptive therapeutic solutions to treat prostate, kidney and bladder cancer¹.
a breakthrough method
Francis Medical is committed to developing urological cancer treatments that are tough on cancer and gentle on patients, with a compassionate belief that cancer tissue can be ablated with minimally invasive treatments. The foundation of the company is a tribute to and legacy for the inventor’s father Francis Hoey whose life was ended by prostate cancer with treatments that had harsh implications on his normal daily living.
water vapor technology
Convective water vapor energy technology is a platform to treat a variety of endourological conditions beginning with Benign Prostatic Hyperplasia (BPH), which was cleared by FDA in 2015 and launched soon thereafter as the Rezum® System. The technology applies the thermal energy stored in sterile water vapor to convectively deliver targeted treatments to the cancerous prostate tissue in a simple transurethral procedure.
October 19th, 2019
Francis Medical, Inc. announced the appointment of Dr. Jonathan Jarow as the company’s chief medical officer (CMO). Dr. Jarow will be leading Francis Medical’s clinical and regulatory efforts, including the VAPOR trials evaluating water vapor ablation as a minimally invasive treatment for prostate cancer.
December 13th, 2018
Francis Medical, Inc., a Minneapolis-based, privately held medical device company developing an innovative and proprietary vapor ablation therapy to treat a variety of endourology cancers, beginning with Prostate Cancer (PCa), today announced the completion of a $18.0 million round of Series A financing.